Navigation Links
7 or 8 Hours of Sleep Best for Health
Date:12/4/2007

Shorter, longer rest periods were tied to increased death risk, research shows

TUESDAY, Dec. 4 (HealthDay News) -- Too much or too little sleep can boost your risk of death, British researchers report.

"In terms of prevention, our findings indicate that consistently sleeping seven or eight hours a night is optimal for health," study author Jane E. Ferrie, of University College London Medical School, said in a prepared statement.

Her team studied more than 8,000 people, aged 35 to 55, who were followed for a number of years.

Among participants who slept six, seven or eight hours a night at the start of the study, a decrease in nightly sleep duration was associated with a 110 percent excess risk of cardiovascular-related death.

Similarly, among those who slept seven or eight hours per night at the start of the study, an increase in nightly sleep duration was associated with a 110 percent excess risk of non-cardiovascular death.

The study appears in the Dec. 1 issue of Sleep.

On average, most adults need seven to eight hours of sleep per night to feel well-rested and alert, according to the American Academy of Sleep Medicine.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about sleep.



-- Robert Preidt



SOURCE: American Academy of Sleep Medicine, news release, Dec. 1, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

0

GOOD

Page: 1

Related medicine news :

1. Limiting Residents Hours Has Little Impact on Patient Mortality
2. Study finds limiting work hours for surgical residents enhances training
3. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
4. Crossfit Workout Challenge Raises Over $500,000 in Four Hours for Athletes for a Cure
5. Pelosi: In 48 Hours, Congress Must Choose Between Meeting the Needs of Americas Children or Not
6. Out of hours doctors reluctant to do home visits, say patients
7. Out-of-hours doctors reluctant to do home visits, say patients
8. Time to Set Kids Back-to-School Sleep Clocks
9. AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic
10. Sleepless Kids Are Troubled Kids
11. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)... a more convenient regimen than current therapies ... The drug ustekinumab has been shown to be a very ...rate-to-severe psoriasis in two studies published ...umab works by binding to two interleukins, protein...mmatory reactions in diseases like psoriasis. The ...
(Date:5/15/2008)...leadership in proposing prescription,drug marketin...PRNewswire-USNewswire/ -- AARP strongly believes,N...vernor,s prescription,marketing reform proposals w...al companies have over prescribing decisions that ...eatment they receive., The reforms include bannin...
(Date:5/15/2008)...ide cancer incidence, researchers at the Moores Ca... (UCSD) and the Department of Family and Preventiv...deficiency in exposure to sunlight, specifically u...posure triggers photosynthesis of vitamin D3 in th...hrough diet and supplements. , Approximately 1,...
(Date:5/15/2008)...e-FirstCall/ -- Pharmasset, Inc.,(Nasdaq: VRUS ),... to,discovering, developing and commercializing no...dited financial results for the second fiscal,quar...t loss attributable,to common stockholders of $12....ded March 31, 2008, as compared to a net loss attr...
Breaking Medicine News(10 mins):Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
...cizumab (Avastin) for first time treatment of adva... // This comes after a large randomised study on l...ancer specialist and director of Thoracic Oncology...Nearly 900 patients with non-small cell lung cance...
...f the world today, Britain had to face the embarra...in Europe' last week. //In a recent report by CABE...h of the nation's population can be declared obese...rchitecture and the Built Environment (CABE) with ...
...d a judicial probe to investigate a botched catara... which 38 people were blinded.// Health Minister ...ucted by a retired judge of the Gauhati High Court... the report in three months. "We are taking the i...
...us type C (GBV-C) protects against HIV infection i...ment of Veterans Affairs (VA) Iowa// City Health C...ied a protein segment that strongly inhibits HIV f...found that an 85-amino acid segment within a GBV-C...
Other Medicine News:Health News:Judicial Probe Ordered for Botched Eye Surgery Camp 2Health News:Study IDs Protein That Inhibits HIV From Growing In Cell Cultures 2Health News:Study IDs Protein That Inhibits HIV From Growing In Cell Cultures 3
(Date:5/15/2008)... -- Ergonex Pharma today,announced that the United...nted orphan drug designation to Terguride for the .... Terguride is currently being evaluated for PAH,i... grant of orphan drug designation to Terguride for...ogram by offering regulatory,clinical development...
(Date:5/15/2008)...l/ -- Novavax, Inc. (Nasdaq:,NVAX) today announced...Ia,study of its pandemic influenza vaccine includi...e interim results from the first phase of the stud...ult volunteers, were,reported in December 2007. Th...ell tolerated and immunogenic at the 15 microgram ...
(Date:5/15/2008)...ata reports in third quarter ...-FirstCall/ -- VIA Pharmaceuticals,Inc. (Nasdaq: ...velopment of,compounds for the treatment of cardio...leted patient enrollment in its acute coronary syn...hase 2 trials investigating VIA-2291,the company,...
(Date:5/15/2008)...ga 3 fatty acids bound to,phospholipids deserves t...rnative and may have beneficial effect on impulsiv...reveals. While several studies have reported,benef...researchers have,hypothesized that Vectomega(R) co...rol., These research findings have led to the ini...
Breaking Medicine Technology:Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 2Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Fish devastated by sex changing chemicals in municipal wastewater 12090 1Fish devastated by sex changing chemicals in municipal wastewater 12090 2Fish devastated by sex changing chemicals in municipal wastewater 12090 360 Minutes to Report on Dangers of Trasylol 3A Cory Watson Crowder 26 DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 12087 160 Minutes to Report on Dangers of Trasylol 3A Cory Watson Crowder 26 DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG 12087 2From stem cells to organs 3A The bioengineering challenge 2231 1From stem cells to organs 3A The bioengineering challenge 2231 2USC and second sight announce European clinical trial for Argus II retinal implant 3347 1USC and second sight announce European clinical trial for Argus II retinal implant 3347 2USC and second sight announce European clinical trial for Argus II retinal implant 3347 3
...wswire-FirstCall/ -- On Wednesday,July 11, 2007, ...Central European Time members of Cell Therapeutics...nce call to discuss today,s,announcement of the in...aring CHOP-R to CPOP-R, in which pixantrone is sub...rst-line treatment of patients,with aggressive non...
...ting Editor , ,Celiac disease (CD) is an auto... that is triggered in genetically susceptible pers...ns wheat, rye, barley, and possibly oats. The cond...both a T-cell and B-cell immune response, leading ...t hyperplasia, and is self-perpetuating with conti...
Other Medicine Technology:Cell Therapeutics, Inc. Management to Discuss Today's Announcement,of Interim Pixantrone Study Results 2Non-Invasive Diagnostic Tests for Celiac Disease 2Non-Invasive Diagnostic Tests for Celiac Disease 3
Transfuse-ID™, a bedside Transfusion Verification System, is used by hospitals to ensure that a patient receives the specific unit(s) of blood that was typed and crossmatched for them. It has th
...stem helps ensure a safe care environment by autom...he unit dose level. The automated process and reli...ion and handling of all items, including vials, am...reparations and more. This saves valuable time for...
...nsfusion Safety Management system ensures your pat...care. , BloodTrack SafeTx uses the AutoPPI™ b...nt from sample collection to transfusion. SafeTx c...uces the need for bedside paperwork and associated...
wBloodCare™ provides functionality at the bedside to ensure that the correct patient receives the correct blood product.
Medicine Products: